Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk is teaming up with GoodRx to offer Wegovey and Ozempic for a flat price of $499 a month. Top Air Force general ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...

Novo Nordisk A/S (NYSE:NVO) has recently made headlines with its robust financial performance, reporting an 18% sales growth in the first half of 2025. This impressive figure positions Novo Nordisk as ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Canada has approved Novo Nordisk's diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of ...

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

In a notable financial update, Novo Nordisk A/S (NYSE:NVO) has reported an impressive 18% sales growth for the first half of 2025. However, this optimistic growth comes with a caveat: the company has ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.